Hospital-to-home support (H-HOPE) for infants with congenital defects after neonatal surgery and their parents
Official title: Impact of the Hospital to Home: Optimizing Preterm Infant Environment (H-HOPE) Intervention on Infants With Congenital Defects Requiring Neonatal Surgery and Their Parents.
Run by Ann & Robert H Lurie Children's Hospital of Chicago · NCT07372898 · Data updated 2026-11-12
This program tests whether H-HOPE helps infants born with congenital defects who need neonatal surgery — and their parents — improve feeding, growth, early development, and parental mental health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 1 Week to 8 Weeks |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Ann & Robert H Lurie Children's Hospital of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | July 31, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | March 30, 2027 |
| Registry record updated | January 28, 2026 |
| Trial ID | NCT07372898 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are infants born with a congenital defect requiring major neonatal surgery (including congenital heart disease) who are clinically stable, under 48 weeks post-menstrual age, not born before 34 weeks gestation, and enrolled together with one or both parents.
✕Probably not a fit
Patients unlikely to benefit include infants born before 34 weeks, those with nervous system congenital defects, genetic syndromes, history of ECMO or prolonged mechanical ventilation, wards of the state, or infants who remain clinically unstable or require high respiratory support.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study compares the H-HOPE hospital-to-home intervention versus standard ICU care for infants born with congenital defects who require major neonatal surgery and their parents. H-HOPE, previously used in preterm and at-risk infant populations, is delivered while infants are clinically stable and under 48 weeks post-menstrual age, with follow-up at ICU discharge and at 3–4 months. Primary outcomes include pre-feeding behavioral organization, salivary cortisol reactivity, oral feeding progression, growth, and early neurodevelopment measured by tools such as the Test of Infant Motor Performance and Ages and Stages Questionnaire. Secondary outcomes examine parent mental health, parent neuroendocrine measures, parent-infant interactions, and relationships with family living conditions.
Why it matters
Potential benefit: If successful, H-HOPE could speed feeding progress, support better early motor and behavioral development, and reduce parental depression and anxiety, easing the transition from hospital to home.
How similar studies have gone: H-HOPE has shown benefits for neurodevelopment and feeding in healthy and at-risk term and preterm infants, but it has not been previously tested in infants with congenital defects requiring neonatal surgery.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Infants and one or both of their parents, born with a congenital defect and requiring major surgery during the neonatal period, including congenital heart disease. * At the time of H-HOPE initiation, infants must be \<48 weeks post-menstrual age (PMA), clinically stable (no vital sign instability during routine nursing care) on respiratory support \< a nasal cannula at 2 liters per minute, and off all intravenous (IV) pain medications. Exclusion criteria: * Infants born at \<34 weeks gestation, * Infants born with congenital defects involving the nervous system (i.e., spina bifida, congenital hydrocephalus), * Infants with genetic syndromes, * Infants with a history of Extracorporeal Membrane Oxygenation, * Infants with a history of mechanical ventilation lasting 30 or more days, or * Infants that are wards of the state.
Where it's running
-
Ann & Robert H Lurie Children's Hospital
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Susan Horner, PhD — Ann & Robert H Lurie Children's Hospital of Chicago
- Study coordinator: Susan Horner, PhD
- Email: shorner@luriechildrens.org
- Phone: 16309158541
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Micronutrient Enhancement for Development and Health in Adolescent Girls
This study tests whether daily micronutrient supplements (MMS or MMS+), compared with weekly iron-folic acid, can improve school performance and growth in 10- to 18-year-old girls in rural Bangladesh.
-
Turkish BRIEF version of the Hammersmith Infant Neurological Examination (HINE)
This project tests a short Turkish BRIEF-HINE neurological screening for infants who are at high risk of neurodevelopmental problems to see if it works well in routine clinics.
-
MOM-CARE: enhanced micronutrient supplements during and after pregnancy to help babies be born healthier and grow better
This will test whether an enhanced multivitamin supplement (MMS Plus) given during pregnancy and after birth helps babies born to women in peri-urban Karachi have better birth outcomes and faster early growth than standard MMS or iron/folic acid.
-
Kangaroo care with a mother's voice and fetal positioning to help preterm babies feed and grow
This test tries daily skin-to-skin time with a mother's storytelling plus fetal positioning in preterm infants (30–34 weeks) to see if it improves comfort, growth, and the move to full oral feeding.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.